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Cryptococcus neoformans is the third most common cause of infectious complications in the central nervous system in AIDS patients: 15 1 million new cases of cryptococcal meningitis occur each year causing ~600,000 deaths. 16 Aspergillus fumigatus is the most common cause of invasive mycoses by filamentous fungi, with mortality rates of 40%-90%. 17, 18 Antifungal drugs Antifungal resistance is an increasing threat for the effective treatment of invasive mycoses, making their therapy difficult, expensive, or even impossible. 10 The current treatment approaches for IFIs are fairly limited and include three main classes of drugs: polyenes (amphotericin B [AmB]), azoles (fluconazole, isavuconazole, itraconazole, posaconazole, and voriconazole), and echinocandins (anidulafungin, caspofungin, and mycafungin). 18 To obtain good clinical results in the treatment, early and appropriate treatment is required, but the activity of current antifungal agents is not predictably against emerging yeasts and filamentous fungi and can cause undesirable side effects. 19 Older antifungal agents, such as AmB, despite their toxicity, are very important in the treatment of IFIs as they have a broad-spectrum and low resistance rates. 20 Recent advances in antifungal chemotherapy with broadspectrum triazoles and echinocandins provide more effective and less toxic alternatives to conventional polyenes. Despite this, IFI mortality rates remain high, and there is a growing need for new therapeutic options. 21 However, the rate of discovery of antifungal drugs is unlikely to be sufficient for the future demands, since few drugs are currently being discovered. In the early 1990s, two new antifungal drugs were approved by the US Food and Drug Administration (FDA), namely, fluconazole and itraconazole. 22 Still in the 1990s, lipid formulations of AmB, amphotericin B lipid complex (ABLC, in 1995), amphotericin B colloidal dispersion (ABCD, in 1996) , and liposomal AmB (L-AmB, in 1997) were all approved. In the 2000s, caspofungin (in 2001) and voriconazole (in 2002) 23 were also approved. Micafungin was the second echinocandin antifungal agent approved by the FDA in 2005 and anidulafungin was the third to be approved in 2006. 24 Posaconazole was approved in 2006 as oral suspension, and in 2013 and 2014 for use in tablets and intravenously, respectively. 22 More recently, in March 2015, the FDA approved isavuconazole 25 ( Figure 1 ). Given the current panorama of microbial resistance and lack of new drugs, NPs appear to aid in the treatment of various diseases, including mycoses. 26 NPs can be defined as ultradispersed supramolecular structures with submicrometer 
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Nanostructured drug delivery systems for fungal diseases size ranging from 10 µm to 1,000 µm. The drug may be dissolved, entrapped, encapsulated, or bound to a matrix of NPs, which acts as a reservoir for particulate systems and therefore plays an important role as a drug delivery system for clinical applications, particularly in oncology. 27 Many studies have currently demonstrated the efficacy of antifungal agents incorporated into NPs for combating fungal infections. [6] [7] [8] The production of NPs through nanotechnology has revolutionized the delivery of drugs. Today, there is a consensus that nanotechnology represents a miniaturization of objects, as well as the preparation of nanomaterials with physical and chemical properties that drastically differ from those of bulk materials because they are on a nanoscale. Until the early 1970s, the administration of pharmaceutical suspensions intravenously was considered impossible due to the risk of embolism. The current development of suspensions of NPs containing drugs (eg, nanomedicines or nanopharmaceuticals) is the use of NPs for treating, diagnosing, and preventing diseases. Through these, it is possible to increase the therapeutic index of various drugs by improving activity, reducing toxicity, and targeting them selectively toward diseased tissues and cells.
A noteworthy problem in the treatment of many diseases, including invasive mycoses, is the delivery of the drug to the target site, since the conventional drugs have limitations such as restricted efficacy, poor biodistribution, and lack of selectivity. The solution to this problem is the use of a drug delivery control system that can overcome these limitations and drawbacks. The therapy based on a delivery system is important to solve problems, regarding the balance between high drug concentrations and toxic effects. A major technological breakthrough in medicine has been the reduction in the particle size from micrometers to nanometers. 28 Through small dimensions, NPs can target specific sites within the body as cells and tissues are permeable to them. Therefore, NPs can deliver the active drug to sites where conventional drugs do not reach, thus minimizing unwanted side effects. The therapeutic potential of NPs as carriers of drugs depends on their hydrodynamic size, shape, quantity, surface chemistry, route of administration, length of stay in circulation, and reaction with the immune system. Nanostructures exhibit unique physicochemical and biological properties, which makes them a favorable material for biomedical applications. 26, 29 Nanoscale structures, or nanosized structures, can be used to carry drugs such as liposomes, synthetic and natural polymers, inorganic and metal NPs, dendrimers, silica, and carbon materials, as well as magnetic NPs (MNPs) 30, 31 ( Figure 2 ).
Lipid-associated formulations
Lipid formulations involve the association of an antifungal drug, such as AmB or nystatin, with a lipid delivery system to reduce toxicity. 33, 34 Three different lipid formulations of AmB have been introduced in the clinical setting. The lipid composition and molecular structure of these formulations vary considerably with unique pharmacokinetic profiles. Although there is evidence of the safety of these formulations, the impact of their unique structure and pharmacokinetic differences for specific clinical efficacy is unproven. 35 AmB deoxycholate (D-AmB) is a polyene macrolide available for clinical use since its initial FDA approval in 1959. 36 AmB is produced through a fermentation process by soil actinomycete Streptomyces nodosus. The AmB has broad spectrum of action and has been considered the gold standard of antifungal therapy for many years, despite being associated with a high incidence of adverse effects related to infusion and nephrotoxicity. 36, 37 D-AmB still has a place in the antifungal therapy but newer drugs (eg, AmB associated with lipid formulations, fluconazole and voriconazole, or caspofungin and micafungin) are being used as first-line treatment options. 38 Fluconazol represented a major advance in the treatment of invasive candidiasis because of its broad activity, excellent tolerability, and favorable pharmacokinetics. Since its introduction, fluconazole has been widely used for the treatment and prophylaxis of candidiasis, except for those infections caused by C. krusei, C. glabrata, or other species with reduced susceptibility or resistance to this drug. 39 Lipid complex and colloidal dispersion and was initially approved in the UK in 1994 and by the FDA in December 1996. 27 The first lipid-based formulation developed was ABLC by associating AmB with a lipiddrug delivery vehicle. ABLC consists of AmB in complex with two phospholipids at 1:1 drug-to-lipid molar ratio. Both phospholipids, l-α-dimyristoylphosphatidylcholine and l-α-dimyristoylphosphatidylglycerol, are present at 7:3 molar ratio. ABLC is characterized by lipid-stabilized AmB aggregates, which appear as ribbon-like structures, with length ranging from 1.6 nm to 11.1 nm, and because of its size, circulating AmB serum concentrations are lower when compared to D-AmB. 35 ABCD consists of 1:1 molar ratio of AmB and cholesterol sulfate, a highly organized structure formed by a natural metabolite of cholesterol. A noncovalent complex of AmB and cholesteryl sulfate forms a tetramer consisting of a hydrophilic and a hydrophobic part.
These add-in spiral arms form a disk-like structure with a diameter of ~122 nm and thickness of 4 nm. 40 Although ABCD reduces the availability of AmB in the kidneys reducing the nephrotoxicity, this drug concentration increases in the endothelial reticulum system, 41, 42 as well as the ABLC formulation. 35 Both ABCD and ABLC are quickly endocyted by the endothelial reticulum system and distributed into the tissue. 43 ABLC formulations demonstrated efficacy against fungi such as Fusarium solani, 44 Candida dubliniensis, 45 A. fumigatus, 46 Aspergillus quadrilineatus, 47 C. neoformans, 48 and Rhizopus oryzae. 49 Table 1 lists the activity of ABCL and ABCD formulations against different fungi.
ABCD exhibits dose-limiting, infusion-related toxicities; 35 consequently, the dosages administered should not exceed 3-4 mg/kg/d. ABCD formulation was not effective in the treatment of paracoccidioidomycosis with a dosage of 3 mg/kg/d, the failure of which can possibly be due to dosage, duration, or poor effectiveness of this lipid preparation, 50 although Hanson and Stevens 51 reported in vitro activity against Paracoccidiodes brasiliensis. This formulation is not suitable as a prophylactic antifungal agent for neutropenic patients due to adverse effects related to infusion. 52 ABCD was found at high concentrations in the lungs after treatment, which does not happen with L-AmB, thus being a possible alternative for lung infections. 53 The prophylactic use against pulmonary mycoses by AmB nebulization has been reported. 54, 55 Other drugs, such as itraconazole, in colloidal dispersion could also be suitable for nebulization. 56 
Liposomes
Liposomes are other type of lipid formulations, consisting of unilamellar or multilamellar layers on the membrane of lipids such as phospholipids, surrounded by aqueous compartment. 60, 61 The liposomes can carry hydrophilic drugs in the aqueous core and increase penetration through the lipophilic membranes, as well as lipophilic drugs, which are inserted into the lipid bilayer, increasing their solubility in aqueous body fluids. 68 Liposomes provide a better protection than other lipid formulations against external degradation by enzymes. In addition, they are biocompatible and biodegradable. 62, 63 Conventional liposomes have some limitations, such as little instability and difficult to be stored for long periods and rapid uptake by the RES, thereby decreasing their half-life in circulation. 69 To solve these problems, extensive research has been developed to modify the surface of liposomes, to optimize their size, and to understanding their mechanisms of action. New generation liposomes are characterized by high mechanical stability, ability to induce or to inhibit the 
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Nanostructured drug delivery systems for fungal diseases immune system, longer bypass, high loading efficiency, ease of interaction with the cell membrane, and increased target specificity. The milestone in the development of the new generation of liposomes is to control drug release. 68 Indeed, the progress in pharmacology has introduced a number of potent therapeutic agents requiring drug carriers that are selective and bioresponsive. Advances in the technology of liposomes as drug delivery systems include long-circulating liposomes, for example, liposomes prepared with hydrophilic polymers on their surface (eg, polyethylene glycol), reduce both uptake by reticuloendothelial system and toxicity of the encapsulated drug. 64, 70 This camouflage allows liposomes to exhibit the abovementioned functions. However, there is the disadvantage of an inhibited cellular absorption, limiting their uptake by macrophages and tumor cells. Hatakeyama et al 71 developed cleavable polyethylene glycol (PEG)-lipids to solve the problem of cellular uptake inhibition, since PEG systems are separated in response to the target tissue microenvironment. The target specificity is achieved by anchoring targeting ligands that bind to the desired receptors. 72 The number of plates or cross-linking lipids controls the rate of drug release from liposomes. 73 Approximately 50 years after the discovery of liposomes, the FDA approved 13 liposome-based products for human 80 and pulmonary aspergillosis. 81, 82 However, in 2013, Ariano et al 83 reported that L-AmB may not be adequate to control lung infections by Blastomyces dermatitidis. Al Nakeeb et al 82 found that lipid formulations of AmB can induce dose-dependent reduction in lung injury markers and circulating fungal biomarkers. The recommended therapeutic dosages are 3-6 mg/kg/d. 35 A clinical dose of L-AmB 3 mg/ kg/d may cause complete suppression of both galactomannan and levels of 1,3-β-d-glucan in most patients with invasive aspergillosis. 82 The literature reports some problems associated with administration of L-AmB, such as hepatotoxicity, 84 progressive leukoencephalopathy, 85, 86 and also development of lysosomal storage disease. 87 Treatment failures have also been reported. 88, 89 The prophylactic use of L-AmB in immunocompromised patients is still a challenge. Mihara et al 90 report that prophylaxis with aerosolized L-AmB was not effective in animal model. Therefore, prospective studies are needed to compare this formulation with triazoles. In addition to AmB, other antifungal agents are carried by liposomal delivery systems, such as nystatin. 33, 34 L-AmB could be useful for the treatment of cryptococcosis, 91 including species of Aspergillus, 92 C. dubliniensis.
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L-AmB also has activity against fungal biofilms. Schinabeck et al 94 were the first to describe Candida biofilm infection of catheters in animal models treated with L-AmB to block the infection. In addition, L-AmB was effective to eradicate Candida biofilm in a continuous catheter flow model, 95 and Ramage et al 96 showed that L-AmB kills C. albicans biofilms rapidly and effectively in a dose-dependent manner.
The need to improve treatment outcomes for IFI increased interest in exploring an alternative antifungal strategy. The administration of AmB in aerosol, which has been widely used, to provide the drug directly to the site of infection or fungal colonization, has the potential to maximize their spectrum of activity while minimizing systemic toxicity that is associated with parenteral administration. Aerosol AmB is used (usually as a prophylactic strategy) in high-risk patients. 97 The literature reports few studies regarding delivery systems based on aerosol for fungal infections, including AmB to prevent pulmonary aspergillosis, 98 C. neoformans, 89 and C. albicans. Table 2 shows the studies with L-AmB and L-AmB formulations associated with other conventional antifungal drugs for the treatment of IFIs in immunocompromised patients, including studies on in vitro activity of L-AmB against different fungi.
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In addition to the liposomal preparation of AmB, there are AmB-polyaggregates with similar efficacy to that of D-AmB and L-AmB in the treatment of a murine-disseminated infection by C. glabrata. 120 Souza et al 129 tested an alternative delivery system to D-AmB, the NANO-D-AmB that has antifungal efficacy against P. brasiliensis with lower levels of cytotoxicity compared to that of D-AmB formulation both in vivo and in vitro, thus confirming a better delivery of AmB.
NPs based on solid lipid nanoparticles and nanostructured lipid carriers
Solid lipid nanoparticles (SLNs) emerged as a new class of colloidal drug carriers at the beginning of the 1990s, and their application has been widely exploited as drug delivery in the area of pharmaceutics, clinical medicine, and therapy. Polymeric NPs (PNPs) have the advantage of promoting chemical modifications, but there are some limitations such as polymer degradation, high cost, and difficult approval by regulatory authorities. 130 Thus, the attention of several research groups has been focused on an alternative to PNPs, that is, the SLNs. 131 SLNs provide physical stability as incorporated drugs do not suffer degradation, have controlled release, and excellent tolerability. Therefore, they can be used by different routes of administration, such as parenteral, 132 peroral, 133 dermal, 134 ocular, 135 pulmonary, 136 and rectal. 137 SLNs are a generation of drugs where the liquid lipid (oil) has been replaced by a solid lipid, mainly composed of a dispersed lipid in physiological water or aqueous surfactant solution (Figure 3) . Replacement of liquid lipid by solid lipid represents a milestone for drug controlled release because the mobility of the drug within the solid lipid is usually lower than within the liquid oil, which makes this system performance attractive for pharmaceutical products. 131 The most advanced forms of SLNs are nanostructured lipid carriers (NLCs), lipid-drug conjugates, and polymer lipid hybrid nanoparticles (PLNs). Therefore, NLCs, introduced at the millennium's turn, are made of a solid lipid matrix that traps the liquid lipid in their nanocompartments, 138 which decreases some of the problems associated with SLNs, such as limited drug-loading capacity, expulsion of the drug during storage, suitability of drug release, and physical stability of long-term suspension. 131 Lipid-drug conjugates were developed to increase the drug-loading capacity, whereas PLNs are hybrids of liposome and PNPs developed to carry poorly water-soluble drugs with high encapsulation efficiency and loading capacity and to control the release 
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Nanostructured drug delivery systems for fungal diseases as a low encapsulation efficiency and a poor expulsion of the stored drug. [141] [142] [143] Table 3 shows some studies on SLN transport systems in antifungal therapy for the therapy of fungal infections. However, scientific evidence on infection treated with the SLN system is scarce.
NLCs are produced by a lipid mixture of liquid and solid phases with increased content of NPs. 27 Mathpal et al 144 have recently conducted a study using a spraying technique for pulmonary delivery of AmB-NCL and concluded that through this technique the drugs are better distributed throughout the lung tissue. Several antifungal agents were also tested in different SLN and NLC delivery systems, such as itraconazole-loaded SLNs, 130, 145 itraconazole-loaded NLC, 146, 147 miconazole nitrate-loaded NLC, 148 econazole nitrate-loaded NLC, 149 and voriconazole 150 (Table 3) . PNPs and nanosuspensions would present clear advantages over of drugs. Moreover, PLNs show excellent serum stability and a wide spectrum of different target cells. 139, 140 The presence of a solid lipid matrix can cause problems in the production of SLNs, since this matrix system is subject to crystallization during its formation, resulting in some drawbacks such 
Polymeric NPs
PNPs are polymeric colloidal systems, which have a diameter ,1 µm, in which the drug can be dissolved, coated, encapsulated, or dispersed. 29, 159 Polymer degradation, high cost, and difficult approval by regulatory authorities are some of the disadvantages. 131 PNPs are stable in the gastrointestinal environment and protect encapsulated drugs against gastrointestinal pH, degradation enzymes, and efflux pumps, maintaining the stability of the drugs in this unfavorable environment. 160 The use of polymers to form PNPs provides flexibility due to their physicochemical properties (eg, size, surface charge, and hydrophobicity), allowing a controlled drug release. In addition, it is possible to modulate the surface properties or use different polymer conjugates on the surface of PNPs. 161 The possibility to add antibodies, peptides, or small molecules to the polymer surface allows tissuespecific interactions with cell receptors or components. 162 Moreover, PNPs enable the encapsulation of a broad range of therapeutic drugs and molecules, such as DNA and small interfering RNA. 160 PNPs are classified into two categories: nanospheres and nanocapsules. Nanocapsules are vesicular systems in which the drug is inside an aqueous or oily cavity surrounded by a polymeric membrane, whereas nanospheres are matrix systems in which the drug is physically and uniformly dispersed in the matrix. 163 These delivery systems have been developed primarily for parenteral, oral, or ocular administration. There are several polymers for preparing PNPs, such as poly-ε-caprolactone, 164 polyacrylamide, 165 polyacrylate, 166 DNA, 167 chitosan, [167] [168] [169] and gelatin. 170 After a polymerization reaction, drugs may be immobilized on the surface of the PNPs 171 or encapsulated in their structure during the polymerization processing. 172 The release of the drug may occur by desorption, diffusion, or erosion of PNPs in the target tissue. 29 However, during the storage time, aggregation of NPs can occur and form precipitates. Other chemical stability problems regarding the polymer or other raw materials have been described, which obstruct their industrial applicability. 173 Inorganic NPs, including gold, iron oxide, silver, or silica, among others, are investigated in preclinical and clinical studies for the treatment, diagnosis, and detection of many diseases. Moreover, many inorganic compounds serving as the material for making NPs have been widely used in clinical practice for several therapeutic applications. 174 One example of therapeutic compounds that act as antibacterial agents is silver ions. [175] [176] [177] Inorganic NPs offer diagnostic and therapeutic opportunity that other PNPs or not, cannot offer. 174 PNPs have some problems arising from residues of organic solvents used in the production process, such as 
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Nanostructured drug delivery systems for fungal diseases cytotoxicity of the polymer and complex production for industrial application. In many production processes, the concentration of NPs is low not exceeding 2%, 178 which compromises their use. Thus, the development of solid dosage forms of NPs is a point of interest in research. Examples of antifungal agents and metal particles associated with PNPs used as drug delivery systems are shown in Table 4 .
Dendrimers
Dendrimers present synthetic polymeric architectures with low polydispersion and controlled surface features. Dendrimers have three main architectural components, namely, core, dendrons, and surface-active groups. 196, 197 There are some ways to connect biologically active compounds to dendrimers: the drug can be encapsulated in the internal structure of the dendrimers 198 or chemically linked or physically adsorbed onto the surface of them. 199 The choice of the immobilization method will depend on the characteristics of the drug.
Several families of dendrimers have been widely studied regarding their use in biomedical sciences. Most well-known dendrimers include polyamidoamines, polypropyleneimines, poly-l-lysines, carbosilanes, and phosphorous dendrimers. Their properties are often not satisfactory because of the high cytotoxicity of the nanomolecules and their low solubility and biocompatibility. Thus, dendrimers are often subjected to various modifications in order to improve their features: dendrimer conjugate with PEG, 200 carbohydrates, 201 or acetyl groups 202 to reduce the cytotoxicity. The compounds bound to dendrimers can improve the surface activity as well as their biological and physical properties. Several specific ligands can be adsorbed, including folic acid, 203 antibodies, 204 target cyclic peptides containing arginine-glycine-aspartic acid, 205 and PEG. Studies involving nanotechnology and medically important fungi have demonstrated improvements in the antifungal properties, such as bioavailability, toxicity, and target tissue, for some drugs, such as AmB, which can facilitate innovative therapeutic approaches. Nanotechnology offers the possibility of multifunctional systems to meet the many different biological and therapeutic requirements. 85 The ultimate therapeutic goal will be to select a drug that can effectively cure the disease without causing side effects. 217 In the near future, the use of nanosystems for drug delivery can be attractive strategies for delivering peptides, nuclear acids, or drugs. 218 In addition, mucoadhesive systems can promote a more specific targeting and retention of the delivery system in humans, such as mucosal surfaces, gastrointestinal tract, lung, genitourinary tract, nasal, and ocular systems. In combination with excellent technological platforms, nanotechnological strategies can increase the bioavailability of antifungal drugs. 
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There are few studies on the antifungal activity enhanced by dendrimers. Polyamidoamine dendrimers were shown to improve the solubility of clotrimazole and enhance its antifungal activity against different species of Candida. 207 According to Janiszewska et al, 208 the antifungal activity of dendrimeric lipopeptides causes morphological changes in fungal cells and inhibition of enzyme activity candidal 1,3-β-d-glucan synthase. Staniszewska et al 209 reported in vitro effects of the dendrimer D186 on the virulence factors of C. albicans, where there was a reduction in adhesive properties and potential of the pathogenic yeast.
Other delivery systems
The antifungal activity in other delivery systems, such as carbon nanotubes, MNPs, and silica NPs, has been less studied. Carbon nanotubes have been one of the most exploited biomedical applications of NPs in the world. Benincasa et al 210 showed that AmB conjugated to carbon nanotubes presented an excellent activity against clinical isolates of Candida spp. The antimicrobial activity against bacteria and fungi (C. albicans) was also demonstrated by scanning electron microscopy, showing that microbial cells were wrapped or entrapped by carbon nanotube networks. 211 Reduced graphene oxide nanosheets have antifungal activity against Aspergillus niger, Aspergillus oryzae, and Fusarium oxysporum. 212 In 2014, Ciu et al 213 showed graphene oxide as a novel two-dimensional nanomaterial for applications in health biomedical with antifungal properties and low cost.
Hussein-Al-Ali et al 214 demonstrated the antimicrobial activity of MNPs loaded with ampicillin to form a nanocomposite decreases the activity of C. albicans. Niemirowicz et al 215 also reported an inhibition of the growth of C. albicans by using MNPs that can be removed from human plasma, blood, serum, and abdominal and cerebrospinal fluids.
Conclusion and future prospects
There is a clear need to find new therapeutic alternatives for IFIs as the number of drugs is reduced and there is an increased resistance to antifungal agents, mainly in emerging fungi such as non-C. albicans species. Moreover, many of the current drugs show toxicity. Thus, a major disadvantage of the polyene antifungal agents, such as D-AmB, is their clinically significant toxicity, although the development of lipid formulations of AmB has reduced this problem. 35 Lipid formulations of AmB preserve renal function and survival of critically ill patients suffering from IFIs. However, these formulations are very expensive and are not globally available.
